Drug Trial Radar · NCT07363642
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jan 28, 2026
Primary completion
Feb 7, 2028
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
Conditions
- Severe Asthma
Interventions
TezepelumabDrug
Severe asthma taking medium-high dose ICS-LABA with up to one additional controller will be enrolled into this single arm treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma controlTime frame: within 36 weeks after the first administration
- To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma controlTime frame: within 36 weeks after the first administration
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Binzhou, China · Recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Changsha, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chongqing, China · Recruiting
Research Site
Chongqing, China · Recruiting
Research Site
Deyang, China · Recruiting
Research Site
Fuzhou, China · Recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guiyang, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hefei, China · Recruiting
Research Site
Hefei, China · Recruiting
Research Site
Hohhot, China · Recruiting
Research Site
Jiangmen, China · Recruiting
Research Site
Jinan, China · Recruiting
Research Site
Jinan, China · Recruiting
Research Site
Jinan, China · Recruiting
Research Site
Jining, China · Recruiting
Research Site
Kunming, China · Not yet recruiting
Research Site
Leshan, China · Recruiting
Research Site
Linyi, China · Recruiting
Research Site
Luzhou, China · Recruiting
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.